Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Nov 4;30(11):2076-2086.
doi: 10.1093/ibd/izad295.

The Epidemiology of Inflammatory Bowel Disease in Oceania: A Systematic Review and Meta-Analysis of Incidence and Prevalence

Angela J Forbes  1 , Chris M A Frampton  1 , Andrew S Day  2 , Gilaad G Kaplan  3   4 , Richard B Gearry  1
Affiliations
Meta-Analysis

The Epidemiology of Inflammatory Bowel Disease in Oceania: A Systematic Review and Meta-Analysis of Incidence and Prevalence

Angela J Forbes et al. Inflamm Bowel Dis. .

Abstract

Background: Past studies have shown high rates of inflammatory bowel disease (IBD) in Australia and New Zealand (NZ). We aimed to describe the epidemiology of IBD in Australia, NZ, and the surrounding region (collectively termed Oceania) by conducting a systematic review and meta-analysis.

Methods: Electronic databases were searched from inception to April 2023 for studies reporting incidence or prevalence rates of IBD, Crohn's disease (CD), or ulcerative colitis (UC) in Oceania. All study designs were included. A meta-analysis calculated pooled estimates of incidence and prevalence, and a sensitivity analysis compared the pooled population-based studies with the non-population-based studies and the Australian and NZ studies separately.

Results: Nineteen incidence and 11 prevalence studies were included; 2 studies were from the Pacific Islands, with the rest coming from Australia and NZ. Pooled estimates showed high incidence rates of 19.8 (95% confidence interval [CI], 15.8-23.7) for IBD, 8.3 (95% CI, 6.9-9.8) for CD, and 7.4 (95% CI, 5.7-9.1) for CD per 100 000 person-years. CD was more common than UC in most studies. The pooled estimates for the prevalence studies were 303.3 (95% CI, 128.1-478.4) for IBD, 149.8 (95% CI, 71.0-228.5) for CD, and 142.2 (95% CI, 63.1-221.4) for UC per 100 000 persons. Studies using population-based data collection methods showed higher pooled rates for both incidence and prevalence.

Conclusions: The incidence and prevalence of IBD in Oceania is high. The studies were heterogeneous and there were several geographic areas with no information, highlighting the need for more epidemiological studies of IBD.

Keywords: Australia; New Zealand; Oceania; epidemiology; incidence; prevalence.

Plain language summary

This systematic review and meta-analysis of inflammatory bowel disease in Oceania found high incidence rates (19.8 [95% confidence interval, 15.8-23.7] per 100 000 person-years) and prevalence rates (303.3 [95% confidence interval, 128.1-478.4] per 100 000 persons). Most studies were from Australasia, with only 2 from the Pacific Islands.

PubMed Disclaimer

Conflict of interest statement

A.J.F. has received a Department of Medicine PhD scholarship. R.B.G. has served on the advisory board or speakers bureau or received research funding from AbbVie, Janssen, Pharmaco, Takeda, and Zespri. C.M.A.F. has no financial disclosures. A.S.D. has received research support from Cure Kids. G.G.K. has received personal fees from AbbVie, Amgen, Janssen, Pfizer, Sandoz, and Pendophram; has received grants from Ferring, AbbVie, Bristol Myers Squibb, Fresenius Kabi, Janssen, Pfizer, and Takeda; and had a patent for the treatment of inflammatory disorders, autoimmune disease, and PBC (UTI Limited Partnership, assignee; patent WO2019046959A1. PCT/CA2018/051098).

Figures

Figure 1.
Figure 1.
Study selection process. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Figure 2.
Figure 2.
Inflammatory bowel disease (IBD), Crohn’s disease (CD), ulcerative colitis (UC), and IBD unclassified (IBDU) incidence rates. AU, Australia; NZ, New Zealand.
Figure 3.
Figure 3.
Inflammatory bowel disease (IBD), Crohn’s disease (CD), ulcerative colitis (UC), and IBD unclassified (IBDU) prevalence rates. AU, Australia; NZ, New Zealand.
See this image and copyright information in PMC

References

    1. Buie MJ, Quan J, Windsor JW, et al. ; Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group. Global hospitalization trends for Crohn’s disease and ulcerative colitis in the 21st Century: a systematic review with temporal analyses. Clin Gastroenterol Hepatol. 2023;21(9):2211-2221. - PubMed
    1. Burisch J, Zhao M, Odes S, et al. . The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2023;8(5):458-492. - PubMed
    1. King JA, Underwood FE, Panaccione N, et al. . Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. Lancet Gastroenterol Hepatol. 2019;4(4):287-295. - PubMed
    1. Kaplan GG, Ng SC.. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152(2):313-321.e2. - PubMed
    1. Molodecky NA, Soon IS, Rabi DM, et al. . Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54.e42; quiz e30. - PubMed

Publication types